We have detected that you are using Internet Explorer to visit this website. Internet Explorer is now being phased out by Microsoft. As a result, NHS Digital no longer supports any version of Internet Explorer for our web-based products, as it involves considerable extra effort and expense, which cannot be justified from public funds. Some features on this site will not work. You should use a modern browser such as Edge, Chrome, Firefox, or Safari. If you have difficulty installing or accessing a different browser, contact your IT support team.
The National Diabetes Audit Insulin Pump Report 2015-16Audit, Survey, Other reports and statistics, Official statistics
- Publication Date:
- 13 Jul 2017
- Geographic Coverage:
- Geographical Granularity:
- NHS Trusts, Clinical Commissioning Groups, Primary Care Trusts, GP practices
- Date Range:
- 01 Jan 2015 to 31 Mar 2016
The Insulin Pump Audit is part of the National Diabetes Audit programme (NDA), and is commissioned by the Healthcare Quality Improvement Partnership (HQIP) as part of the National Clinical Audit programme (NCA). The NDA is managed by NHS Digital (formerly the Health and Social Care Information Centre (HSCIC)) in collaboration with Diabetes UK and supported by Public Health England (PHE).
The Insulin Pump Audit collects information on the number and characteristics of people with diabetes using an insulin pump, the reason for going on an insulin pump and the outcomes achieved since starting the pump.
The guidance states that Continuous Subcutaneous Insulin Infusion (CSII) or 'insulin pump' therapy is recommended as a treatment option for adults and children 12 years and over with Type 1 diabetes mellitus if:
-attempts to reach target haemoglobin A1c (HbA1c) levels with multiple daily injections result in the person having 'disabling hypoglycaemia', or
-HbA1c levels have remained high (69mmol (8.5 per cent) or above) with multiple daily injections (including using long-acting insulin analogues if appropriate) despite the person and/or their carer carefully trying to manage their diabetes CSII therapy is not recommended as treatment for people with Type 2 diabetes mellitus.